Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Office-Based Buprenorphine Treatment

Office-Based Buprenorphine Treatment Abstract Opiate addiction is a serious global health issue that profoundly impacts the welfare of populations around the world. Opioid addiction affects an estimated 1.9 million individuals in the United States alone, stimulating a rise in treatment options such as medication-assisted treatment with buprenorphine. When combined with counseling and relapse prevention groups, medication-assisted treatment has proven to be an effective office-based opioid treatment for opiate dependence. Office-based opioid treatment has broadened access to treatment of opioid dependence, has decreased the risk for overdose, and is effective for reducing cravings and opioid use at proper dosing levels. However, treatment retention and relapse remain significant challenges. The purpose of this study was to identify characteristics predictive of retention in treatment time of opioid-dependent individuals receiving office-based buprenorphine treatment. The records of individuals enrolled in a public health office buprenorphine clinic (n = 350) were analyzed to determine retention time in treatment and whether retention time varied by selected individual variables. Participants in the study had a cumulative predicted retention time on buprenorphine of 65% at 30 days, 35% at 6 months, 25% at 12 months, and 18% at 18 months. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Addictions Nursing Wolters Kluwer Health

Office-Based Buprenorphine Treatment

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/office-based-buprenorphine-treatment-gDEeGYPedR
Publisher
Wolters Kluwer Health
Copyright
Copyright © 2020 International Nurses Society on Addictions
ISSN
1088-4602
eISSN
1548-7148
DOI
10.1097/JAN.0000000000000320
Publisher site
See Article on Publisher Site

Abstract

Abstract Opiate addiction is a serious global health issue that profoundly impacts the welfare of populations around the world. Opioid addiction affects an estimated 1.9 million individuals in the United States alone, stimulating a rise in treatment options such as medication-assisted treatment with buprenorphine. When combined with counseling and relapse prevention groups, medication-assisted treatment has proven to be an effective office-based opioid treatment for opiate dependence. Office-based opioid treatment has broadened access to treatment of opioid dependence, has decreased the risk for overdose, and is effective for reducing cravings and opioid use at proper dosing levels. However, treatment retention and relapse remain significant challenges. The purpose of this study was to identify characteristics predictive of retention in treatment time of opioid-dependent individuals receiving office-based buprenorphine treatment. The records of individuals enrolled in a public health office buprenorphine clinic (n = 350) were analyzed to determine retention time in treatment and whether retention time varied by selected individual variables. Participants in the study had a cumulative predicted retention time on buprenorphine of 65% at 30 days, 35% at 6 months, 25% at 12 months, and 18% at 18 months.

Journal

Journal of Addictions Nursing – Wolters Kluwer Health

Published: Jan 1, 2020

References

  • Five-year experience with collaborative care of opioid addicted patients using buprenorphine in primary care
    Alford, D.; LaBelle, C.; Kretsch, N.; Bergeron, A.; Winter, M.; Botticelli, M.; & Samet, J.
  • Web-based injury statistics query and reporting system (WISQARS)
  • Treatment engagement of individuals experiencing mental illness: Review and update
    Dixon, L.; Holoshitz, Y.; & Nossel, I.
  • Effect of buprenorphine dose on treatment outcome
    Fareed, A.; Vayalapalli, S.; Casarella, J.; & Drexler, K.
  • The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013
    Florence, C. S.; Zhou, C.; Luo, F.; & Xu, L.
  • Integrating buprenorphine treatment into a public healthcare system: The San Francisco Department of Public Health's office-based buprenorphine pilot program
    Hersh, D.; Little, S.; & Gleghorn, A.
  • Nonparametric estimation from incomplete observations
    Kaplan, E. L.; & Meier, P.
  • Effective treatments for opioid addiction
  • Medications to treat opioid addiction
  • Opioid crisis
  • Drug overdose death in New Mexico
  • New Mexico substance abuse epidemiology profile
  • Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy
    Parren, T.; Adelman, C.; Merkin, B.; Pagano, M.; Defranco, R.; Lonescu, R.; & Mace, A.
  • The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment
    Pinto, H.; Maskrey, V.; Swift, L.; Rumball, D.; Wagle, A.; & Holland, R.
  • Increases in drug and opioid-involved overdose deaths—United States, 2010–2015
    Rudd, R. A.; Seth, P.; David, F.; & Scholl, L.
  • Buprenorphine clinic for opioid maintenance therapy: Program description, process measures, and patient satisfaction
    Strobbe, S.; Mathias, L.; Gibbons, P.; Humenay, E.; & Brower, K.
  • Compliance with buprenorphine medication-assisted treatment and relapse to opioid use
    Tkacz, J.; Severt, J.; Cacciola, J.; & Ruetsch, C.
  • Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug related overdoses and deaths
  • Adjunctive counseling during brief and extended buprenorphine–naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial
    Weiss, R. D.; Potter, J.; Fiellin, D.; Byrne, M.; Connery, H.; Dickinson, W.; … Ling, W.